Browsing by Subject "Brain aging"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    15 Years of Longitudinal Genetic, Clinical, Cognitive, Imaging, and Biochemical Measures in DIAN
    (medRxiv, 2024-08-09) Daniels, Alisha J.; McDade, Eric; Llibre-Guerra, Jorge J.; Xiong, Chengjie; Perrin, Richard J.; Ibanez, Laura; Supnet-Bell, Charlene; Cruchaga, Carlos; Goate, Alison; Renton, Alan E.; Benzinger, Tammie L. S.; Gordon, Brian A.; Hassenstab, Jason; Karch, Celeste; Popp, Brent; Levey, Allan; Morris, John; Buckles, Virginia; Allegri, Ricardo F.; Chrem, Patricio; Berman, Sarah B.; Chhatwal, Jasmeer P.; Farlow, Martin R.; Fox, Nick C.; Day, Gregory S.; Ikeuchi, Takeshi; Jucker, Mathias; Lee, Jae-Hong; Levin, Johannes; Lopera, Francisco; Takada, Leonel; Sosa, Ana Luisa; Martins, Ralph; Mori, Hiroshi; Noble, James M.; Salloway, Stephen; Huey, Edward; Rosa-Neto, Pedro; Sánchez-Valle, Raquel; Schofield, Peter R.; Roh, Jee Hoon; Bateman, Randall J.; Dominantly Inherited Alzheimer Network; Neurology, School of Medicine
    This manuscript describes and summarizes the Dominantly Inherited Alzheimer Network Observational Study (DIAN Obs), highlighting the wealth of longitudinal data, samples, and results from this human cohort study of brain aging and a rare monogenic form of Alzheimer's disease (AD). DIAN Obs is an international collaborative longitudinal study initiated in 2008 with support from the National Institute on Aging (NIA), designed to obtain comprehensive and uniform data on brain biology and function in individuals at risk for autosomal dominant AD (ADAD). ADAD gene mutations in the amyloid protein precursor (APP), presenilin 1 (PSEN1), or presenilin 2 (PSEN2) genes are deterministic causes of ADAD, with virtually full penetrance, and a predictable age at symptomatic onset. Data and specimens collected are derived from full clinical assessments, including neurologic and physical examinations, extensive cognitive batteries, structural and functional neuro-imaging, amyloid and tau pathological measures using positron emission tomography (PET), flurordeoxyglucose (FDG) PET, cerebrospinal fluid and blood collection (plasma, serum, and whole blood), extensive genetic and multi-omic analyses, and brain donation upon death. This comprehensive evaluation of the human nervous system is performed longitudinally in both mutation carriers and family non-carriers, providing one of the deepest and broadest evaluations of the human brain across decades and through AD progression. These extensive data sets and samples are available for researchers to address scientific questions on the human brain, aging, and AD.
  • Thumbnail Image
    Item
    Brain gray matter reduction and premature brain aging after breast cancer chemotherapy: a longitudinal multicenter data pooling analysis
    (Springer, 2023) de Ruiter, Michiel B.; Deardorff, Rachael L.; Blommaert, Jeroen; Chen, Bihong T.; Dumas, Julie A.; Schagen, Sanne B.; Sunaert, Stefan; Wang, Lei; Cimprich, Bernadine; Peltier, Scott; Dittus, Kim; Newhouse, Paul A.; Silverman, Daniel H.; Schroyen, Gwen; Deprez, Sabine; Saykin, Andrew J.; McDonald, Brenna C.; Radiology and Imaging Sciences, School of Medicine
    Brain gray matter (GM) reductions have been reported after breast cancer chemotherapy, typically in small and/or cross-sectional cohorts, most commonly using voxel-based morphometry (VBM). There has been little examination of approaches such as deformation-based morphometry (DBM), machine-learning-based brain aging metrics, or the relationship of clinical and demographic risk factors to GM reduction. This international data pooling study begins to address these questions. Participants included breast cancer patients treated with (CT+, n = 183) and without (CT-, n = 155) chemotherapy and noncancer controls (NC, n = 145), scanned pre- and post-chemotherapy or comparable intervals. VBM and DBM examined GM volume. Estimated brain aging was compared to chronological aging. Correlation analyses examined associations between VBM, DBM, and brain age, and between neuroimaging outcomes, baseline age, and time since chemotherapy completion. CT+ showed longitudinal GM volume reductions, primarily in frontal regions, with a broader spatial extent on DBM than VBM. CT- showed smaller clusters of GM reduction using both methods. Predicted brain aging was significantly greater in CT+ than NC, and older baseline age correlated with greater brain aging. Time since chemotherapy negatively correlated with brain aging and annual GM loss. This large-scale data pooling analysis confirmed findings of frontal lobe GM reduction after breast cancer chemotherapy. Milder changes were evident in patients not receiving chemotherapy. CT+ also demonstrated premature brain aging relative to NC, particularly at older age, but showed evidence for at least partial GM recovery over time. When validated in future studies, such knowledge could assist in weighing the risks and benefits of treatment strategies.
  • Thumbnail Image
    Item
    Brain-age prediction: Systematic evaluation of site effects, and sample age range and size
    (Wiley, 2024) Yu, Yuetong; Cui, Hao-Qi; Haas, Shalaila S.; New, Faye; Sanford, Nicole; Yu, Kevin; Zhan, Denghuang; Yang, Guoyuan; Gao, Jia-Hong; Wei, Dongtao; Qiu, Jiang; Banaj, Nerisa; Boomsma, Dorret I.; Breier, Alan; Brodaty, Henry; Buckner, Randy L.; Buitelaar, Jan K.; Cannon, Dara M.; Caseras, Xavier; Clark, Vincent P.; Conrod, Patricia J.; Crivello, Fabrice; Crone, Eveline A.; Dannlowski, Udo; Davey, Christopher G.; de Haan, Lieuwe; de Zubicaray, Greig I.; Di Giorgio, Annabella; Fisch, Lukas; Fisher, Simon E.; Franke, Barbara; Glahn, David C.; Grotegerd, Dominik; Gruber, Oliver; Gur, Raquel E.; Gur, Ruben C.; Hahn, Tim; Harrison, Ben J.; Hatton, Sean; Hickie, Ian B.; Hulshoff Pol, Hilleke E.; Jamieson, Alec J.; Jernigan, Terry L.; Jiang, Jiyang; Kalnin, Andrew J.; Kang, Sim; Kochan, Nicole A.; Kraus, Anna; Lagopoulos, Jim; Lazaro, Luisa; McDonald, Brenna C.; McDonald, Colm; McMahon, Katie L.; Mwangi, Benson; Piras, Fabrizio; Rodriguez-Cruces, Raul; Royer, Jessica; Sachdev, Perminder S.; Satterthwaite, Theodore D.; Saykin, Andrew J.; Schumann, Gunter; Sevaggi, Pierluigi; Smoller, Jordan W.; Soares, Jair C.; Spalletta, Gianfranco; Tamnes, Christian K.; Trollor, Julian N.; Van't Ent, Dennis; Vecchio, Daniela; Walter, Henrik; Wang, Yang; Weber, Bernd; Wen, Wei; Wierenga, Lara M.; Williams, Steven C. R.; Wu, Mon-Ju; Zunta-Soares, Giovana B.; Bernhardt, Boris; Thompson, Paul; Frangou, Sophia; Ge, Ruiyang; ENIGMA-Lifespan Working Group; Psychiatry, School of Medicine
    Structural neuroimaging data have been used to compute an estimate of the biological age of the brain (brain-age) which has been associated with other biologically and behaviorally meaningful measures of brain development and aging. The ongoing research interest in brain-age has highlighted the need for robust and publicly available brain-age models pre-trained on data from large samples of healthy individuals. To address this need we have previously released a developmental brain-age model. Here we expand this work to develop, empirically validate, and disseminate a pre-trained brain-age model to cover most of the human lifespan. To achieve this, we selected the best-performing model after systematically examining the impact of seven site harmonization strategies, age range, and sample size on brain-age prediction in a discovery sample of brain morphometric measures from 35,683 healthy individuals (age range: 5-90 years; 53.59% female). The pre-trained models were tested for cross-dataset generalizability in an independent sample comprising 2101 healthy individuals (age range: 8-80 years; 55.35% female) and for longitudinal consistency in a further sample comprising 377 healthy individuals (age range: 9-25 years; 49.87% female). This empirical examination yielded the following findings: (1) the accuracy of age prediction from morphometry data was higher when no site harmonization was applied; (2) dividing the discovery sample into two age-bins (5-40 and 40-90 years) provided a better balance between model accuracy and explained age variance than other alternatives; (3) model accuracy for brain-age prediction plateaued at a sample size exceeding 1600 participants. These findings have been incorporated into CentileBrain (https://centilebrain.org/#/brainAGE2), an open-science, web-based platform for individualized neuroimaging metrics.
  • Thumbnail Image
    Item
    Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study
    (eLife Sciences, 2023-01-06) Millar, Peter R.; Gordon, Brian A.; Luckett, Patrick H.; Benzinger, Tammie L. S.; Cruchaga, Carlos; Fagan, Anne M.; Hassenstab, Jason J.; Perrin, Richard J.; Schindler, Suzanne E.; Allegri, Ricardo F.; Day, Gregory S.; Farlow, Martin R.; Mori, Hiroshi; Nübling, Georg; The Dominantly Inherited Alzheimer Network; Bateman, Randall J.; Morris, John C.; Ances, Beau M.; Neurology, School of Medicine
    Background: Estimates of 'brain-predicted age' quantify apparent brain age compared to normative trajectories of neuroimaging features. The brain age gap (BAG) between predicted and chronological age is elevated in symptomatic Alzheimer disease (AD) but has not been well explored in presymptomatic AD. Prior studies have typically modeled BAG with structural MRI, but more recently other modalities, including functional connectivity (FC) and multimodal MRI, have been explored. Methods: We trained three models to predict age from FC, structural (S), or multimodal MRI (S+FC) in 390 amyloid-negative cognitively normal (CN/A-) participants (18-89 years old). In independent samples of 144 CN/A-, 154 CN/A+, and 154 cognitively impaired (CI; CDR > 0) participants, we tested relationships between BAG and AD biomarkers of amyloid and tau, as well as a global cognitive composite. Results: All models predicted age in the control training set, with the multimodal model outperforming the unimodal models. All three BAG estimates were significantly elevated in CI compared to controls. FC-BAG was significantly reduced in CN/A+ participants compared to CN/A-. In CI participants only, elevated S-BAG and S+FC BAG were associated with more advanced AD pathology and lower cognitive performance. Conclusions: Both FC-BAG and S-BAG are elevated in CI participants. However, FC and structural MRI also capture complementary signals. Specifically, FC-BAG may capture a unique biphasic response to presymptomatic AD pathology, while S-BAG may capture pathological progression and cognitive decline in the symptomatic stage. A multimodal age-prediction model improves sensitivity to healthy age differences.